> ## Content Index
> Fetch the complete content index at: https://www.theamericanquorum.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Supreme Court Keeps Mifepristone Rules in Place While FDA Approval Challenge Continues
- URL: https://www.theamericanquorum.com/taq-historical-2023-04-22-healthcare/
- Published: 2023-04-23T03:59:00.000Z
- Updated: 2023-04-23T03:59:00.000Z
- Description: The Supreme Court stayed lower-court restrictions on mifepristone, preserving FDA’s current rules while a major challenge to the agency’s drug-approval authority proceeds on appeal.
- Author: Kenneth R. Deans Jr.
- Tags: Healthcare, #Import 2026-09-01 00:50

The Supreme Court on Friday preserved the existing federal rules for mifepristone while litigation over the abortion drug continues, staying lower-court orders that would have suspended or sharply restricted Food and Drug Administration actions governing a medicine first approved in 2000\. The unsigned order means the current FDA-approved conditions remain in effect while the U.S. Court of Appeals for the Fifth Circuit considers the case and while any subsequent Supreme Court review is pursued.

The Court’s [docket](https://www.supremecourt.gov/docket/docketfiles/html/public/22A902.html?ref=theamericanquorum.com) shows that the stay was granted on April 21 after emergency applications from the federal government and Danco Laboratories, the manufacturer of branded mifepristone. Justice Clarence Thomas said he would have denied the stay, and Justice Samuel Alito filed a dissent. The ruling is procedural rather than a final judgment on the legality of FDA’s approval or later regulatory changes, but its immediate practical effect is substantial: pharmacies, prescribers and patients do not have to adjust to the more restrictive conditions that otherwise could have taken effect.

## A challenge to FDA authority reaches the Supreme Court

The litigation began with physicians and medical organizations challenging a series of FDA decisions spanning more than two decades. A federal district judge in Texas on April 7 stayed the agency’s 2000 approval of mifepristone and subsequent actions. The Fifth Circuit then partially narrowed that order, leaving the original approval in place while restoring older restrictions on how the drug could be prescribed and dispensed.

In its [emergency application](https://www.supremecourt.gov/DocketPDF/22/22A902/263491/20230414103258942%5FAlliance%20for%20Hippocratic%20Med%20%20application.pdf?ref=theamericanquorum.com), the Justice Department argued that the lower courts had overridden FDA’s scientific judgment and would create immediate regulatory disruption. The government emphasized that more than five million Americans had used mifepristone and that FDA had repeatedly reviewed evidence about the drug’s safety and conditions of use. It also argued that the challengers lacked standing because they do not prescribe or take the drug and because their claimed injuries depend on a chain of possible future events.

The challengers, in their [opposition](https://www.supremecourt.gov/DocketPDF/22/22A902/263824/20230418120347639%5F2023.04.18%20Opposition%20to%20Emergency%20Application.pdf?ref=theamericanquorum.com), defended the district court’s intervention and argued that FDA’s actions were unlawful. Their case challenges the agency’s original approval as well as later decisions that expanded the gestational limit, reduced in-person requirements and changed dispensing rules. The dispute therefore reaches beyond abortion policy into administrative law: how much latitude courts should give a specialized federal agency when reviewing drug-safety decisions based on scientific records.

## The regulatory history is central

FDA approved mifepristone in 2000 for use with misoprostol to terminate early pregnancies under specified conditions. In 2016, the agency expanded use from seven to ten weeks of gestation, changed dosing and reduced the number of required in-person visits. In 2019 it approved a generic version. During the pandemic, FDA exercised enforcement discretion over the in-person dispensing requirement, and in 2021 it concluded that the requirement was no longer necessary. A January 2023 modification permitted certified pharmacies to dispense the drug under a risk-management program.

The government’s [reply filing](https://www.supremecourt.gov/DocketPDF/22/22A902/263892/20230418232614640%5FFINAL%20Alliance%20SCOTUS%20Reply.pdf?ref=theamericanquorum.com) stressed the operational consequences of suddenly reverting to older labeling and distribution conditions. Because prescription drugs must be marketed under FDA-authorized labeling, changing the legal conditions of approval could force manufacturers, distributors, pharmacies and clinicians to alter established systems on short notice.

Medical organizations filing as amici argued that the dispute should be evaluated through the accumulated scientific evidence and FDA’s regulatory process. A [brief from medical and public-health societies](https://www.supremecourt.gov/DocketPDF/22/22A902/263645/20230414183024744%5F1009027343v1-AFHM%20v.%20FDA%5FSCOTUS%20Amicus%20Brief%20-%20FDA%20FINAL.PDF?ref=theamericanquorum.com) urged the Court to preserve the status quo while appeals proceed, emphasizing the clinical reliance that has developed around the approved regimen.

## Former FDA officials warn about wider drug regulation

The case has drawn unusual attention from the pharmaceutical and regulatory communities because it asks courts to review not simply a single enforcement decision but a longstanding drug approval and subsequent scientific judgments. A [brief from former FDA officials](https://www.supremecourt.gov/DocketPDF/22/22A902/263649/20230414184241567%5F22A901%20902%20-%20Brief%20of%20Amici%20Curiae%20Former%20FDA%20Officials.pdf?ref=theamericanquorum.com) argued that allowing the district court order to take effect could destabilize the national drug-approval framework by encouraging challenges to agency decisions long after medicines enter routine clinical use.

The challengers dispute that characterization and contend that courts retain authority to set aside agency action that violates federal law or the Administrative Procedure Act. That is a familiar proposition in administrative litigation, but the context is unusual because FDA drug approvals rest on highly technical records and because manufacturers, clinicians and patients build systems around those approvals over time.

The Supreme Court’s stay does not resolve those competing positions. It simply keeps the existing regulatory regime in place while the Fifth Circuit addresses the merits of the appeal. The case could return to the Supreme Court after the appellate court rules.

## A narrow order with immediate national consequences

Justice Alito’s [dissent](https://www.supremecourt.gov/opinions/22pdf/22a901%5F3d9g.pdf?ref=theamericanquorum.com) argued that the applicants had not shown the kind of irreparable harm necessary for emergency relief and pointed to the possibility that FDA could use enforcement discretion if restrictions took effect. The majority did not explain its reasoning, a common feature of emergency orders.

For healthcare organizations, the practical message is clearer than the legal one. Through the appeals process, mifepristone remains available under FDA’s current conditions rather than the older restrictions the Fifth Circuit had allowed to return. That preserves a single federal regulatory standard for the moment and avoids an immediate need to relabel products or restructure dispensing arrangements.

The underlying litigation remains consequential because medication abortion now accounts for a large share of abortions in the United States and because the case tests the relationship between courts and FDA’s scientific authority. Friday’s order settles none of those questions permanently. It does, however, prevent a rapid nationwide change in the drug’s regulatory status while those questions are litigated through the ordinary appellate process.